Table III.

Methodologic index for nonrandomized controlled trials

Authors	Clearly stated aim	Inclusion of consecutive patients	Prospective collection of data	Endpoints appropriate for aim	Unbiased assessment of endpoints	Appropriate follow-up period	Loss to follow-up rate <5%	Prospective calculation of study size	Adequate control group	Contemporary groups	Baseline equivalence of groups	Adequate statistical analysis	Total score
Arnold et al,5 2011	2	1	2	2	2	2	0	0					11
Bell and Coghlan,7 2014	2	2	2	2	1	2	1	0					12
Budge et al,9 2013	2	2	2	2	1	2	1	0					12
Collin et al,12 2011	0	2	2	2	1	2	1	0	2	2	2	2	18
De Wilde et al,14 2013	2	2	2	2	0	2	2	0					12
Denard et al,15 2013	2	1	1	2	1	2	2	0					11
Fox et al,18 2009	2	2	2	2	2	2	2	0	2	2	1	2	21
Fox et al,19 2013	2	2	1	2	1	2	1	0					11
Gazielly and Scarlat,23 2015	2	1	1	2	1	2	2	0					11
Greiner et al,25 2013	0	2	2	2	1	2	1	0					10
Groh,26 2010	2	1	1	2	1	2	2	0					11
Gulotta et al,27 2015	2	1	1	2	1	2	2	2	2	2	2	2	21
Ho et al,28 2013	2	1	2	2	2	2	2	0					13
Hsu et al,29 2014	2	1	1	2	2	2	2	0					12
Kooistra et al,31 2017	0	2	1	2	1	2	2	0	2	2	1	2	17
McLendon et al,35 2017	2	1	1	2	1	2	2	0					11
Merolla et al,36 2016	2	2	1	2	1	2	1	0					11
Nuttall et al,39 2012	2	2	2	2	2	2	1	0					13
Nuttall et al,38 2017	2	2	2	2	2	2	1	0					13
Press et al,42 2014	2	2	2	2	1	2	2	0	2	2	1	2	20
Roche et al,44 2017	1	1	2	2	0	2	1	0	2	2	1	2	16
Service et al,45 2017	1	2	2	2	2	2	1	0					12
Throckmorton et al,47 2010	2	1	1	2	0	2	2	0	2	2	2	2	18
Vidil et al,49 2013	2	2	2	2	0	2	2	0					12
Walch et al,51 2011	2	2	1	2	1	2	1	0					11
Walch et al,50 2012	2	2	1	2	2	2	1	1					13
Wirth et al,53 2012	2	2	1	2	2	2	1	0					12
Young et al,54 2011	1	2	1	2	1	2	1	0					10